Literature DB >> 31969770

WEST NILE VIRUS INFECTION WITH NEUROLOGICAL DISORDERS: A CASE REPORT AND A BRIEF REVIEW OF THE SITUATION IN BULGARIA.

Magdalena Baymakova1, Iva Christova1, Elitsa Panayotova1, Iva Trifonova1, Aleksandar Chobanov1, Ivaylo Daskalov1, Georgi T Popov1, Kamen Plochev1.   

Abstract

A case of a 66-year-old man with West Nile neuroinvassive disease manifested with fever, weakness, fatigue, consciousness disorders and underlying diabetes mellitus type 2 and cardiovascular diseases is presented. Laboratory data showed elevated erythrocyte sedimentation rate and fibrinogen. Serological tests revealed West Nile virus specific antibodies of class IgM and IgG in serum. West Nile virus RNA was detected in urine sample. Supportive therapy was applied.

Entities:  

Keywords:  Antibodies; Bulgaria; Case reports; Nervous system diseases; RNA, Viral; West Nile fever; West Nile virus

Mesh:

Year:  2019        PMID: 31969770      PMCID: PMC6971811          DOI: 10.20471/acc.2019.58.03.21

Source DB:  PubMed          Journal:  Acta Clin Croat        ISSN: 0353-9466            Impact factor:   0.780


Introduction

West Nile virus (WNV), a single-stranded RNA virus, is a mosquito-borne flavivirus (family Flaviviridae) (). The natural cycle is realized by transmission between mosquitoes of Culex spp. and several bird species (). Horses and humans are incidental dead-end hosts (). Generally, human infections are asymptomatic, acute febrile syndrome is presented in 10%-20% of cases, and less than 1% of them developed neuroinvasive disease (). The first large outbreak in Europe was in Romania in 1996 (). Since then, sporadic cases were reported until another outbreak occurred in Greece in 2010 (). Reports followed on human outbreaks or sporadic cases in countries from south-east Europe (Bulgaria, Croatia, Greece, Romania, Serbia, Turkey) (-). A case report of laboratory confirmed human case of WNV infection with neurological symptoms and favorable outcome is presented.

Case Report

A 66-year-old man presented to the Emergency Center, Military Medical Academy, Sofia, Bulgaria, on September 7, 2016, because of low-grade fever, palpitation, fatigue, extremity weakness, dizziness, headache, and brief loss of consciousness three days before hospital admission. The man had concomitant diabetes mellitus type 2, hypertension, paroxysmal atrial fibrillation, mitral valve regurgitation and tricuspid valve regurgitation. The patient was a retiree and lived in Sofia. He did outdoor activities such as fishing and hiking and mentioned mosquito bites during the summer of 2016. Upon admission, he was afebrile, conscious, with blood pressure 150/80 mm Hg, heart rate 90/min; the rest of physical examination did not show any abnormalities. Neurological examination did not estimate neck stiffness or symptoms of Kernig and Brudzinski at the time of hospitalization. The main laboratory findings were as follows: white blood cell count 7.3x109/L (reference range: 3.5-10.5 x109/L), platelets 144x109/L (150-400x109/L), hemoglobin 146 g/L (130-180g/L), erythrocyte sedimentation rate 50 mm/h (≤20 mm/h), blood glucose 9.4 mmol/L (3.5-5.6 mmol/L), creatinine 112 µmol/L (45-130 µmol/L), urea 4.7 mmol/L (2.8-8.3 mmol/L), aspartate aminotransferase 40 IU/L (5-40 IU/L), alanine aminotransferase 27 IU/L (5-40IU/L), creatine phosphokinase 193 IU/L (≤180IU/L), C-reactive protein 3.6 mg/L (0.0-5.0 mg/L), potassium 4.2 mmol/L (3.5-5.2 mmol/L), sodium 137 mmol/L (136-145 mmol/L), and fibrinogen 5.21 g/L (2.0-4.5g/L). Imaging investigations were done at the beginning of illness. Electrocardiogram, x-ray and abdominal ultrasound did not show any abnormalities. Transthoracic echocardiogram revealed the underlying cardiac pathology. Empirical antimicrobial drug therapy was started (intravenous cefoperazone/sulbactam 1 g twice daily and amikacin 500 mg twice daily). The patient received supportive treatment as well. In a short period of hospitalization, consciousness disorders developed and WNV infection was suspected. The man was transferred to Department of Infectious Diseases. He became aggressive and excitable with a tendency of drowsiness. Neurological examination found right facial palsy and areflexia of lower extremities. No lumbar puncture was performed as the patient refused the invasive procedure. Computed tomography of the head was normal. Serum samples were obtained for serological tests for WNV, TBEV, influenza A virus, influenza B virus and Borrelia burgdorferi. All results were negative except for the positive result for specific IgM antibodies against WNV in serum sample. On day 7 of the illness, second blood and urine samples were obtained and transferred to the National Reference Laboratory of Vector-Borne Infections, Department of Microbiology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria. Specific WNV-IgM antibodies were detected in serum (Anti-WNV ELISA IgM, Euroimmun, Lübeck, Germany), but specific WNV-IgG antibodies were not found (Anti-WNV ELISA IgG, Euroimmun, Lübeck, Germany). Blood and urine samples were tested for WNV RNA using a commercial kit (Sacace Biotechnologies, Como, Italy). The results were negative. One week later, blood and urine samples were obtained for confirmation. The level of IgM antibodies was elevated and specific IgG antibodies against WNV were detected. WNV RNA was detected in urine sample by real-time polymerase chain reaction (PCR). Blood cultures showed no bacterial growth. Neurological manifestations were reversible and in a few days the patient regained normal consciousness. After complex therapy, the patient was discharged. On three-month follow-up, the patient was free from any neurological complications.

Discussion

Bulgaria is situated in the south-east part of Europe, with Mediterranean climate, a field for migratory and overwintering birds. During the last decades, the neighboring countries reported human WNV outbreaks and sporadic cases in new areas (-). In the 2011-2016 period, the Bulgarian Reference Laboratory of Vector-Borne Infections (Sofia, Bulgaria) reported only nine human cases, of which six cases fulfilled the EU criteria for probable WNV cases and three cases were laboratory confirmed (-, ). During these six years, only three confirmed human cases at the time of increasing emergence of WNV in Europe were recorded. It is logically to expect more human cases in Bulgaria because of the favorable geographic location, suitable climate factors, vectors, and an increasing incidence of cases along the Danube River and in northern Greece. The seroprevalence of WNV among healthy people in Bulgaria in 11 provinces of the country showed the highest WNV seropositivity in the Sofia district (). Hadjichristodoulou et al. report 2.1% WNV seropositivity in Greece (). Kalaycioglu et al. and Gazi et al. identified seroprevalence of WNV in Turkey of 3.8% and 4.3%, respectively (, ). Obviously, the levels of WNV seropositivity are similar across south-east Europe. The surveillance systems, veterinary control, medical attention to this infection and collaboration among different institutions in Bulgaria are unsatisfactory. Medical doctors should actively search for WNV infection and epidemiological data on mosquito bites in case of acute febrile syndrome with/without neurological signs in summer/autumn season (July-October). The clinical case of WNV infection presented was an elderly man with concomitant diseases. Male gender is reported as predominant in Serbian and Romanian reports of WNV cases (, ). Mean age of more than 65 years and diabetes are significantly associated with encephalitis, as reported by Popovic et al. (). Hypertension is one of the main underlying conditions estimated in European outbreaks (, , ). Notably, these concomitant diseases increased the chance for WNV manifestation with neuroinvasive disease in patients presenting neurological signs, while involvement of the nervous system in the development of WNV infection has been recognized as a tendency in the last decade in Europe, mainly associated with establishment of WNV lineage 2 in the continent (, ). In conclusion, a case report of a 66-year-old man with underlying diabetes mellitus type 2 and cardiovascular diseases, who developed consciousness disturbances and neurological signs as a result of neuroinvasive infection with WNV is presented. The etiological agent was laboratory confirmed based on the EU recommendation (). Specific antibodies of IgM and IgG classes against WNV were found in serum samples. WNV RNA was detected by real-time PCR in urine sample (). Complex clinical symptoms, physical findings and laboratory investigations confirmed the clinical case of WNV infection in an elderly man with neurological signs, who recovered without consequences.
  19 in total

1.  Ongoing outbreak of West Nile virus infections in humans in Greece, July-August 2010.

Authors:  A Papa; K Danis; A Baka; A Bakas; G Dougas; T Lytras; G Theocharopoulos; D Chrysagis; E Vassiliadou; F Kamaria; A Liona; K Mellou; G Saroglou; T Panagiotopoulos
Journal:  Euro Surveill       Date:  2010-08-26

2.  Emergence of West Nile virus infections in humans in Turkey, 2010 to 2011.

Authors:  H Kalaycioglu; G Korukluoglu; A Ozkul; O Oncul; S Tosun; O Karabay; A Gozalan; Y Uyar; D Y Caglayık; G Atasoylu; A B Altas; S Yolbakan; T N Ozden; F Bayrakdar; N Sezak; T S Pelıtlı; Z O Kurtcebe; E Aydın; M Ertek
Journal:  Euro Surveill       Date:  2012-05-24

3.  West Nile encephalitis epidemic in southeastern Romania.

Authors:  T F Tsai; F Popovici; C Cernescu; G L Campbell; N I Nedelcu
Journal:  Lancet       Date:  1998-09-05       Impact factor: 79.321

4.  West Nile virus circulation in South-Eastern Romania, 2011 to 2013.

Authors:  S Dinu; A I Cotar; I R Pănculescu-Gătej; E Fălcuţă; F L Prioteasa; A Sîrbu; G Oprişan; D Bădescu; P Reiter; C S Ceianu
Journal:  Euro Surveill       Date:  2015-05-21

Review 5.  West Nile virus.

Authors:  Shannan L Rossi; Ted M Ross; Jared D Evans
Journal:  Clin Lab Med       Date:  2010-03       Impact factor: 1.935

Review 6.  West Nile virus in Europe: emergence, epidemiology, diagnosis, treatment, and prevention.

Authors:  V Sambri; M Capobianchi; R Charrel; M Fyodorova; P Gaibani; E Gould; M Niedrig; A Papa; A Pierro; G Rossini; S Varani; C Vocale; M P Landini
Journal:  Clin Microbiol Infect       Date:  2013-04-17       Impact factor: 8.067

7.  Phylogenetic characterization of Central/Southern European lineage 2 West Nile virus: analysis of human outbreaks in Italy and Greece, 2013-2014.

Authors:  L Barzon; A Papa; E Lavezzo; E Franchin; M Pacenti; A Sinigaglia; G Masi; M Trevisan; L Squarzon; S Toppo; E Papadopoulou; N Nowotny; S Ulbert; A Piralla; F Rovida; F Baldanti; E Percivalle; G Palù
Journal:  Clin Microbiol Infect       Date:  2015-07-31       Impact factor: 8.067

8.  Concurrent occurrence of human and equine West Nile virus infections in Central Anatolia, Turkey: the first evidence for circulation of lineage 1 viruses.

Authors:  Aykut Ozkul; Koray Ergunay; Aydan Koysuren; Feray Alkan; Ethem M Arsava; Seda Tezcan; Gurol Emekdas; Sabri Hacioglu; Mahur Turan; Durdal Us
Journal:  Int J Infect Dis       Date:  2013-03-19       Impact factor: 3.623

9.  Epidemiology of West Nile disease in Europe and in the Mediterranean Basin from 2009 to 2013.

Authors:  Daria Di Sabatino; Rossana Bruno; Francesca Sauro; Maria Luisa Danzetta; Francesca Cito; Simona Iannetti; Valeria Narcisi; Fabrizio De Massis; Paolo Calistri
Journal:  Biomed Res Int       Date:  2014-09-11       Impact factor: 3.411

10.  West Nile Virus Seroprevalence in the Greek Population in 2013: A Nationwide Cross-Sectional Survey.

Authors:  Christos Hadjichristodoulou; Spyros Pournaras; Maria Mavrouli; Andriani Marka; Persefoni Tserkezou; Agoritsa Baka; Charalambos Billinis; Antonios Katsioulis; Anna Psaroulaki; Anna Papa; Nikos Papadopoulos; Zissis Mamuris; Athanasios Tsakris; Jenny Kremastinou
Journal:  PLoS One       Date:  2015-11-25       Impact factor: 3.240

View more
  1 in total

1.  Cauda equina arachnoiditis - a rare manifestation of West Nile virus neuroinvasive disease: A case report.

Authors:  Marija Santini; Ivana Zupetic; Klaudija Viskovic; Juraj Krznaric; Marko Kutlesa; Vladimir Krajinovic; Vlatka Lovrakovic Polak; Vladimir Savic; Irena Tabain; Ljubo Barbic; Maja Bogdanic; Vladimir Stevanovic; Anna Mrzljak; Tatjana Vilibic-Cavlek
Journal:  World J Clin Cases       Date:  2020-09-06       Impact factor: 1.337

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.